Publications by authors named "A Prat"

Claim this Profile
T
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Aleix Prat

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.
Marcin Kubeczko, Andrea d'Amico, Olgierd Chrabanski, Daria Handkiewicz-Junak, Anna Polakiewicz-Gilowska, Aleix Prat

Breast Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.
Alicia Escudero, Meritxell Bellet, Cristina Saura, Anna Aguilera, Andri Papakonstantinou, Aleix Prat

Cancer Treat Rev· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Alexandre Prat

Mult Scler· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications.
Gaia Griguolo, Michele Bottosso, Laia Paré, Federica Miglietta, Daniele Giulio Generali, Aleix Prat

NPJ Breast Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis